BAX vs HAE
BAX: Baxter International is a leading medical technology company delivering critical life-sustaining therapies for patients with complex medical conditions in hospitals and at home. HAE: Haemonetics provides essential technologies for blood and plasma collection, as well as specialized medical devices for hospital procedures and hemostasis management.
Side-by-side fundamentals
| Metric | BAX | HAE | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $26.34 | $108.80 | |
| Market cap as of 2026-08-24 | $13.6B | $5.0B | |
| P/E as of 2026-08-24 | n/a | 43.22 | |
| PEG as of 2026-08-24 | -0.02 | n/a | |
| Net margin as of 2026-08-24 | -9.3% | +7.1% | HAE higher |
| Gross margin as of 2026-08-24 | +30.7% | +59.1% | HAE higher |
| Operating margin as of 2026-08-24 | -2.3% | +11.9% | HAE higher |
| ROE as of 2026-08-24 | -16.6% | +11.3% | HAE higher |
| ROA as of 2026-08-24 | -5.3% | +4.0% | HAE higher |
| Debt / equity as of 2026-08-24 | 1.52 | 1.40 | HAE lower |
| Revenue growth (YoY) as of 2026-08-24 | +5.4% | +0.4% | BAX higher |
| Revenue CAGR (3y) SEC XBRL | +3.8% | +4.5% | HAE higher |
| Dividend yield as of 2026-08-24 | +3.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-08-24 | 0.65 | 0.63 | |
| 1-year return as of 2026-08-21 close | +10.4% | +101.6% | HAE higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.